$IO Biotech (IOBT.US)$Reuters· 08:051min IO Biotech Completes Enrollment in Phase 2 Trial of Its Investigational, off-the-Shelf Therapeutic Cancer Vaccine, IO102-IO103, as Neoadjuvant/Adjuvant Treatment for Patients With Resectable Melanoma or Head and Neck Cancer
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more